- Cascades Inc. CAS CADNF price target has been lowered to C$15 from C$17 by RBC Capital analyst Paul C. Quinn after the Q1 results.
- The analyst maintained the Outperform rating on the shares.
- Quinn mentions that the company reported 1Q22 Adjusted EBITDA of $58 million, which was well below their $89 million forecast and consensus of $90 million.
- Shares were down ~23% following the release of results. Quinn thinks that demonstrating improving performance in the Tissue business will be critical over the next couple of quarters.
- Price Action: CAS shares are trading higher by 7.10% at C$9.81 on TSX, and CADNF is higher by 11.97% at $7.86 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Analyst ColorNewsPrice TargetReiterationSmall CapAnalyst RatingsMoversTrading IdeasBriefsCanadawhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
